Gujarat Themis Biosyn bulk deals, insider trading and stake changes
NSE: GUJTHEMBSE: 506879Pharmaceuticals & BiotechnologySmall Cap
Last close ₹324.00down ₹29.40 (8.32%)BSE ₹327.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹353.40.
52-week range of traded prices to 23 Oct 2026
₹225.05Low, 30 Mar 2026₹479.00High, 27 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹4,217 Cr886th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Aug 2026
- 86.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.21%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 7 Aug 2026
- 18.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 Jun 2026
- 0.56
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 9,32,72750.2% delivered
Promoter and insider buying and selling
Trades made since 23 Oct 2025.Gujarat Themis Biosyn promoter holding
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Gujarat Themis Biosyn insider trading
All 17 disclosures on record. The company's own latest disclosure on record is from Dec 2023.Insider trading, all companies
Mar 2026
- MR. R S CHOUHAN₹0.07 Cr2,500 sharesBought · Designated Person · 9 Mar 2026 · disclosed 7 Apr
- MR. R S CHOUHAN₹0.08 Cr2,800 sharesSold or invoked · Designated Person · 9 Mar 2026 · disclosed 7 Apr
Dec 2023
- Pharmaceutical Business Group [India] Ltd₹65 Cr30,00,000 sharesSold · Promoter Group · 27 Dec 2023 · disclosed 28 Dec · held 3,71,60,000 before, holds 3,41,60,000 after
Sep 2023
- Mrs.Avantika Vijay Agarwal₹0.49 Cr5,400 sharesBought · Directors Immediate Relative · 26 Sep 2023 · disclosed 27 Sep · stake 0.07% before, 0.10% after
Dec 2021
- Mrs.Avantika Vijay Agarwal₹0.19 Cr3,704 sharesSold · Directors Immediate Relative · 15 Dec 2021 · disclosed 17 Dec · stake 0.09% before, 0.07% after
- Ms. Avantika Vijay Agarwal₹0.03 Cr656 sharesSold · Directors Immediate Relative · 14 Dec 2021 · disclosed 15 Dec · stake 0.10% before, 0.09% after
- Ms. Avantika Vijay Agarwal₹0.46 Cr9,032 sharesSold · Directors Immediate Relative · 13 Dec 2021 · disclosed 15 Dec · stake 0.16% before, 0.10% after
Sep 2021
- Pharmaceutical Business Group (India) Limited₹58 Cr38,50,000 sharesReceived · Promoter Group · 17 Sep 2021 · disclosed 18 Sep · Inter-se-Transfer · stake 24.65% before, 51.15% after
- Yuhan Corporation₹58 Cr38,50,000 sharesGave · Promoter Group · 17 Sep 2021 · Inter-se-Transfer · held 38,50,000 before, holds none after
Jun 2021
- Mr.Rajneesh Anand₹0.15 Cr5,250 sharesBought · Designated Person · 16 Jun 2021 · disclosed 17 Jun · stake 0.14% before, 0.17% after
- Mr.Rajneesh Anand₹0.05 Cr1,750 sharesBought · Designated Person · 15 Jun 2021 · disclosed 16 Jun · stake 0.13% before, 0.14% after
Earlier, Mar 2020 to Mar 2021Hide earlier
Mar 2021
- Ms. Indu Vijay Agarwal₹0.11 Cr5,000 sharesSold · Directors Immediate Relative · 10 Mar 2021 · disclosed 12 Mar · stake 0.14% before, 0.11% after
Jun 2020
- Ms. Indu Vijay Agarwal₹0.09 Cr5,000 sharesBought · Directors Immediate Relative · 17 Jun 2020 · disclosed 18 Jun · stake 0.11% before, 0.14% after
- Ms. Indu Vijay Agarwal₹0.19 Cr10,774 sharesBought · Directors Immediate Relative · 16 Jun 2020 · disclosed 17 Jun · stake 0.03% before, 0.11% after
- Ms. Indu Vijay Agarwal₹0.09 Cr4,976 sharesBought · Directors Immediate Relative · 15 Jun 2020 · disclosed 16 Jun · held none before, holds 4,976 after, stake 0.03% after
Mar 2020
- Ms. Avantika Vijay Agarwal₹0.08 Cr8,000 sharesBought · Directors Immediate Relative · 13 Mar 2020 · disclosed 14 Mar · stake 0.10% before, 0.16% after
- Ms. Avantika Vijay Agarwal₹0.16 Cr15,000 sharesBought · Directors Immediate Relative · 11 Mar 2020 · disclosed 12 Mar · held none before, holds 15,000 after, stake 0.10% after
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
Gujarat Themis Biosyn stake sales and purchases
All 2 disclosures on record.
Aug 2026
- AcquiredPharmaceutical Business Group India Ltd, Themis Medicare Limited, Dinesh Shantilal Patel, Jayshree D Patel, Reena S Patel, Sachin Dinesh Patel, Dinesh Shantilal Patel, Anay Rupen Choksi, Nysha Rupen Choksi and Dinesh S Patel (Vividhmargi Trust) · promoterholds 59.33% after28 Aug 2026 · filed under the 2% rule
Jun 2026
- AcquiredSachin D. Patel · promoter2.29% of the company24,97,190 sharesholds 24,97,200 shares after30 Jun 2026 · filed under the 2% rule · Inter-se transfer
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
Gujarat Themis Biosyn bulk deals
Last 12 months, since 23 Oct 2025: 4 bulk deals, ₹22 Cr bought and ₹49 Cr sold Bought and sold in deals. Each deal's shares times its price, added up for the buyers and apart for the sellers, so a block deal, which names both, counts on each side.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Wednesday 23 Sep 20261 firm · ₹41,337 bought · ₹27 Cr soldNet sold ₹27 Cr
- Both waysL7 HITECH PRIVATE LIMITEDBought 100 at ₹413.37Sold 6,53,056 at ₹410.720.50% of the companyNet −6,52,956 shares₹41,337 bought
Friday 24 Apr 20261 firm · ₹22 Cr bought · ₹22 Cr soldNet sold ₹0.02 Cr
- Both waysNK SECURITIES RESEARCH PRIVATE LIMITEDBought 5,90,941 at ₹367.22Sold 5,90,941 at ₹367.480.54% of the companyNet nil₹22 Cr bought
Wednesday 27 Dec 20232 firms · ₹11 Cr bought · ₹65 Cr soldNet sold ₹54 Cr
- SoldPHARMACEUTICAL BUSINESS GROUP I LTDSold 30,00,000 at ₹215.3520.65% of the company₹65 Cr
- BoughtMC JAIN INFOSERVICES PRIVATE LIMITEDBought 4,90,000 at ₹215.003.37% of the company₹11 Cr
Friday 21 Apr 20172 firms · ₹0.38 Cr bought · ₹0.38 Cr soldNet nil
- BoughtMANJU PAREKHBought 75,000 at ₹50.190.52% of the company₹0.38 Cr
- SoldNEELKAMAL MOTILAL PAREKHSold 75,000 at ₹50.190.52% of the company₹0.38 Cr
Monday 16 Mar 20151 firm · ₹0.09 Cr bought · ₹0.36 Cr soldNet sold ₹0.27 Cr
- Both waysPRABHAT PRABHATBought 22,316 at ₹39.31Sold 93,773 at ₹38.260.65% of the companyNet −71,457 shares₹0.09 Cr bought
Friday 13 Mar 20151 firm · ₹0.29 Cr bought · ₹0.03 Cr soldNet bought ₹0.26 Cr
- Both waysPRABHAT PRABHATBought 78,178 at ₹36.61Sold 6,721 at ₹37.900.54% of the companyNet +71,457 shares₹0.29 Cr bought
Monday 18 Aug 20141 firm · ₹0 bought · ₹0.19 Cr soldNet sold ₹0.19 Cr
- SoldM/S MERIT CREDIT COPRATION LIMITEDSold 1,09,589 at ₹17.400.75% of the company₹0.19 Cr
Tuesday 2 Nov 20102 firms · ₹0.35 Cr bought · ₹0.35 Cr soldNet nil
- Both waysRAM GOPALBought 1,80,000 at ₹9.71Sold 1,80,000 at ₹9.431.55% of the companyNet nil₹0.17 Cr bought
- Both waysHIMANSHU TIWARIBought 1,86,454 at ₹9.46Sold 1,86,454 at ₹9.481.61% of the companyNet nil₹0.18 Cr bought
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 16 deals on record from 4 Jan 2004.